Last reviewed · How we verify
Anemia of renal disease
Approved treatments
- Enaroy · Japan Tabacco
- Jesduvroq · GSK
Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production. - Aranesp · University of Washington
- Aranesp · Amgen
Aranesp works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production. - Darbepoetin · NICHD Neonatal Research Network
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Anemia of renal disease patent landscape — cliff calendar, originator estates, attackable patents
- Anemia of renal disease treatment landscape brief
- Anemia of renal disease treatment updates RSS
Frequently asked questions about Anemia of renal disease
What drugs treat Anemia of renal disease?
Tracked treatments include Enaroy, Jesduvroq, Aranesp, Darbepoetin.
What is the treatment for Anemia of renal disease?
Standard treatment for Anemia of renal disease includes Enaroy, Jesduvroq, Aranesp, Darbepoetin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Anemia of renal disease patent cliff · Anemia of renal disease CI report
- Treatment: Enaroy · Japan Tabacco
- Treatment: Jesduvroq · GSK
- Treatment: Aranesp · University of Washington
- Treatment: Aranesp · Amgen
- Treatment: Darbepoetin · NICHD Neonatal Research Network
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing